Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.69 USD
Change Today +0.07 / 0.40%
Volume 8.9K
DSNKY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co-spon adr (DSNKY) Snapshot

Open
$17.63
Previous Close
$17.62
Day High
$17.72
Day Low
$17.60
52 Week High
07/17/14 - $18.77
52 Week Low
01/9/15 - $13.34
Market Cap
12.5B
Average Volume 10 Days
22.2K
EPS TTM
--
Shares Outstanding
709.0M
EX-Date
03/26/15
P/E TM
--
Dividend
$0.51
Dividend Yield
1.43%
Current Stock Chart for DAIICHI SANKYO CO-SPON ADR (DSNKY)

Related News

No related news articles were found.

daiichi sankyo co-spon adr (DSNKY) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co-spon adr (DSNKY) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s product portfolio includes generic pharmaceuticals, vaccines, and over-the-counter (OTC) medicines. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Edoxaban, an anticoagulant; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis; Pralia for osteoporosis; Tenelia for treatment for type 2 diabetes mellitus; and ActHIB, a haemophilus b conjugate vaccine, as well as Denosumab to treat and prevent various bone disorders, including osteoporosis and bone metastases. The company’s products OTC comprise Loxonin S, an analgesic and anti-inflammatory drug; Transino II, a drug for the improvement of spots; and Traful Ointment for stomatitis treatment. It also markets therapies in hypertension, dyslipidemia, and bacterial infections, as well as treatments for thrombotic disorders. In addition, the company researches and develops therapies in oncology and cardiovascular-metabolic diseases, including biologics. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co-spon adr (DSNKY) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥131.0M
Compensation as of Fiscal Year 2014.

daiichi sankyo co-spon adr (DSNKY) Key Developments

Daiichi Sankyo Company, Limited Revises Consolidated Earnings Guidance for the Year Ended March 31, 2015

Daiichi Sankyo Company, Limited revised consolidated earnings guidance for the year ended March 31, 2015. For the year, the company now expects revised revenue of JPY 919,000 million, operating profit of JPY 74,000 million, profit before tax of JPY 79,000 million, profit attributable to owners of the company of JPY 46,000 million or JPY 65.34 basic earnings per share compared to previously provided revenue of JPY 900,000 million, operating profit of JPY 100,000 million, profit before tax of JPY 100,000 million, profit attributable to owners of the company of JPY 65,000 million or JPY 92.33 basic earnings per share.

Daiichi Sankyo Company, Limited's Once-Daily Lixiana® (Edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism

Daiichi Sankyo Company, Limited announced that the European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Lixiana® (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism (SE) in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors. The CHMP also recommended approval of Lixiana for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. The two related conditions DVT and PE are collectively referred to as venous thromboembolism. The CHMP opinion to approve once-daily edoxaban for the prevention of stroke and SE in adult patients with NVAF with one or more risk factors and for the treatment and prevention of recurrent VTE (DVT and PE) is based on the data of the phase 3 ENGAGE AF-TIMI 48 and Hokusai-VTE studies, respectively. In the ENGAGE AF-TIMI 48 study, once-daily edoxaban 60 mg demonstrated non-inferiority to well-managed warfarin for the primary efficacy endpoint of occurrence of stroke or SE in patients with NVAF (1.18% vs. 1.50% per year, respectively; hazard ratio [HR], 0.79; 97.5% confidence interval [CI], 0.63 to 0.99, pAbout the ENGAGE AF-TIMI 48 Study. ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation) was a three-arm, randomized, double-blind, double-dummy, global phase 3 clinical trial comparing once-daily edoxaban with well-managed warfarin in 21,105 patients with NVAF at moderate-to-high risk of thromboembolic events at 1,393 centers in 46 countries. ENGAGE AF-TIMI 48 compared two edoxaban treatment strategies, a higher dose arm (60 mg or 30 mg dose reduced) once-daily and a lower dose arm (30 mg or 15 mg dose reduced) once-daily, with warfarin in patients with NVAF for a median of 2.8 years follow-up. Patients were dose reduced for CrCL 30 to 50 mL/min, body weight of 60 kg or less or certain P-gp inhibitor use. ENGAGE AF-TIMI 48 represents the large and longe single comparative global trial with a novel anticoagulant in patients with NVAF performed to date. The full results were presented at the AHA Scientific Sessions 2013 in Dallas and published in the New England Journal of Medicine.

Daiichi Likely To Sell Stake in Sun Pharma

Dilip Shanghvi is likely to buy stake in Sun Pharmaceutical Industries Limited (BSE:524715) from Daiichi Sankyo Company, Limited (TSE:4568). Shanghvi may buy a partial stake (up to 5%) from Daiichi Sankyo, which holds 8.93% in Sun Pharma.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSNKY:US $17.69 USD +0.07

DSNKY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.15 USD +0.83
BioCryst Pharmaceuticals Inc $9.54 USD +0.175
BioMerieux €95.78 EUR -0.32
Infinity Pharmaceuticals Inc $12.79 USD -0.32
Ipsen SA €51.65 EUR +0.38
View Industry Companies
 

Industry Analysis

DSNKY

Industry Average

Valuation DSNKY Industry Range
Price/Earnings 16.0x
Price/Sales 1.3x
Price/Book 1.3x
Price/Cash Flow 16.1x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO-SPON ADR, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.